Overview

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

Status:
Completed

Trial end date:
2021-08-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if the study drug abemaciclib in combination with other anti-cancer therapies is safe in Japanese participants with advanced cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Abiraterone Acetate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate